The administration of anti-CD19 CAR-T cells into patients with persisting B cell malignancies after allogenic-SCT showed rapid regression of tumors without any evidence of graft-versus-host disease (GVHD), even if patients were refractory to donor lymphocyte infusions (DLIs) [162]. Here, CD19 is linked to graft versus host disease.